(Photo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)
ATS Medical continues to expand its cardiac surgery product portfolio, and
this meeting provides an excellent opportunity to display its array of
offerings for heart valve therapy and surgical ablation of cardiac
arrhythmias. The ATS CryoMaze(TM) system for surgical cryoablation will be
prominently featured. Surgical treatment of cardiac arrhythmias is a topic of
great interest for surgeons and increasing numbers find the ATS CryoMaze
system to be their product of choice. ATS is sponsoring "Frontiers in
Cryoablation," a symposium designed to provide a unique forum for sharing
experiences among physician attendees. ATS Medical's Cryoablation Scientific
Advisory Board members will lead the open discussion in a question and answer
format. The symposium will be held on
The ATS exhibit will also focus on the company's flagship ATS Open Pivot(R) mechanical heart valve franchise, including its newest iteration, the ATS Open Pivot(R) AP360(TM), as well as its newly-approved ATS 3f(R) Aortic Bioprosthesis tissue valve. The AP360(TM) valve's unique open pivot design results in exceptional performance and a low risk profile while the ATS 3f(R) Aortic Bioprosthesis, whose design is based on the precept that "Form Follows Function," is a revolutionary next generation stentless pericardical aortic tissue valve that is unlike any other. Post-approval commercialization of the ATS 3f Aortic Bioprosthesis continues with the valve's unique design and compelling clinical benefits generating enthusiasm and product demand among U.S. surgeons.
The ATS Simulus(R) annuloplasty product line, also featured in ATS'
exhibit, has expanded to include flexible and semi-rigid offerings. ATS
Medical will co-sponsor a symposium entitled "Future-Proof Your Practice With
Technologies Available Now" where respected surgeons will discuss the
integration of new techniques to improve cardiac procedures.
Hands-on demonstrations of all the unique technologies from ATS Medical will be available at the ATS Medical booth #809.
About ATS Medical
ATS Medical, Inc. is dedicated to 'Advancing The Standards' of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.
ATS was originally founded to develop the ATS Open Pivot(R) Heart Valve as a new mechanical heart valve standard of care. Today the Open Pivot heart valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f(R) brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive, sutureless based procedures. The ATS 3f(R) portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus(R) annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze(TM) products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is http://www.atsmedical.com.
Safe Harbor
This Press Release contains forward-looking statements that may include
statements regarding intent, belief or current expectations of the Company and
its management. Actual results could differ materially from those projected in
the forward-looking statements as a result of a number of important factors,
including the results of clinical trials, the timing of regulatory approvals,
the integration of 3f Therapeutics and the surgical cryoablation business of
CryoCath Technologies, Inc., regulatory actions, competition, pricing
pressures, supplier actions and management of growth. For a discussion of
these and other risks and uncertainties that could affect the Company's
activities and results, please refer to the Company's filings with the
Securities and Exchange Commission, including its Form 10-K for the year ended
SOURCE ATS Medical, Inc.